Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.


BACKGROUND The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated. OBJECTIVE To determine primary tumor response to treatment with targeted agents in patients with mRCC. DESIGN, SETTING, AND… (More)
DOI: 10.1016/j.eururo.2010.09.034


7 Figures and Tables

Slides referencing similar topics